Found 455 results in Expert Content

During this webinar, industry experts will navigate the intricate journey of drug development, exploring how minitablets have redefined formulation strategies, efficacy, and patient-centric solutions as well as options for lifecycle management.

Read this case study to learn how a company engaged with Catalent to develop an oral lipid-based formulation that would lead to a more predictable and reliable drug response.

Summary: Explore Catalent’s extensive standalone analytical services with industry leading equipment and network of over 3,000 scientists. Learn how our deep expertise supporting pharmaceuticals, biologics (protein, cell and therapy, and vaccines), inhalation (nasal and dry powder inhaler), drug product/substance and in-process samples could help accelerate your drug product's journey.

In this webinar, experts discuss problems common to the development, testing and manufacturing of intranasal drug products, their potential causes, and possible consequences.

Summary: In this webinar, experts will explore the current investment and clinical landscape of Targeted Protein Degraders.

In a Fireside Chat during the 2024 JP Morgan Healthcare Conference, Catalent President & CEO Alessandro Maselli shared his predictions for 2024 and his thoughts on the top risks and opportunities in Biotech with Endpoints News Editor John Carroll.

Summary: With integrated formulation development, analytical testing, clinical supply and commercial manufacturing solutions for highly potent products, we can help accelerate your program and bring transformative therapies to patients in need.

Summary: This webinar explores formulation and manufacturing strategies, enriched by case studies on lipid-based drug delivery systems and softgels.

Summary: This webinar explores the world of pediatric dosage forms and how ODTs are emerging as a specialized drug delivery system for children.

Summary: Experts explore the challenges of orphan drug development and manufacturing and will discuss how the industry is leveraging strategic partnerships to help mitigate these challenges to create a viable orphan drug business model.